Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VEENA S JOHN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1356475610
CMS profile
629489
Location
LAKE SUCCESS, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$5,280.14

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,110.00 2
Food and Beverage $170.14 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $2,775.29 2
Eisai Inc. $2,370.00 1
ABBVIE INC. $134.85 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VEENA S JOHN

NPI 1356475610 · CMS profile ID 629489

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LAKE SUCCESS, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356475610?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VEENA S JOHN, NPI 1356475610, CMS profile ID 629489. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356475610?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). VEENA S JOHN, NPI 1356475610, CMS profile ID 629489. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356475610?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
VEENA S JOHN, NPI 1356475610, CMS profile ID 629489, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1356475610?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $5,280.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $2,740.0010/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110555084 CMS
Eisai Inc. $2,370.0009/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110787001 CMS
ABBVIE INC. $134.8505/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103999529 CMS
AstraZeneca Pharmaceuticals LP $35.2902/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110538539 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $2,397.50 1
PY2021 $3,384.92 4
PY2022 $8,314.43 8
PY2023 $282.38 3
PY2024 $5,280.14 4
PY2025 $2,749.00 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $117,539.27 115
PY2024 Principal investigator $75,315.93 37
PY2023 Principal investigator $181,942.68 17
PY2022 Principal investigator $644,386.95 38
PY2021 Principal investigator $521,972.74 85
PY2020 Principal investigator $281,344.94 58
PY2019 Principal investigator $495,433.48 82

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $62,626.02 12/31/2020 Non-covered Recipient Entity
Biomedical Research Alliance Of New York
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA) No dispute reported 06/30/2026 736742623
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,360.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133623
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,925.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133625
Principal investigator 1 Deciphera Pharmaceuticals Inc. $550.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133627
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,360.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133629
Principal investigator 1 Deciphera Pharmaceuticals Inc. $550.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133631
Principal investigator 1 Deciphera Pharmaceuticals Inc. $550.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133635
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,142.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133637
Principal investigator 1 Deciphera Pharmaceuticals Inc. $550.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133647
Principal investigator 1 Deciphera Pharmaceuticals Inc. $550.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133649
Principal investigator 1 Deciphera Pharmaceuticals Inc. $550.00 12/24/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737133651
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,102.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132505
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,522.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132507
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,353.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132539
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,157.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132543
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,973.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132563
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,843.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132565
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,973.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132567
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,946.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132669
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,102.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132681
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,964.00 12/04/2020 Non-covered Recipient Entity
NORTHWELL HEALTH CANCER INSTITUTE JOHN
A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 737132683
Principal investigator 1 Merck Sharp & Dohme Corporation $39,083.94 12/01/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769777
Principal investigator 1 GlaxoSmithKline, LLC. $895.00 11/19/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB No dispute reported 06/30/2026 965526059
Principal investigator 1 Genentech, Inc. $1,000.00 11/17/2020 Non-covered Recipient Entity
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857151307
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 11/09/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769489
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 11/09/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769771
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 11/09/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769773
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 11/09/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769775
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 11/09/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769779
Principal investigator 1 Genentech, Inc. $2,523.00 10/26/2020 Non-covered Recipient Entity
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857151331
Principal investigator 1 GlaxoSmithKline, LLC. $6,368.76 09/24/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB No dispute reported 06/30/2026 734921187
Principal investigator 1 Genentech, Inc. $1,682.00 09/01/2020 Non-covered Recipient Entity
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857151325
Principal investigator 1 GlaxoSmithKline, LLC. $14,493.20 08/25/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1021545193
Principal investigator 1 Genentech, Inc. $1,000.00 07/28/2020 Non-covered Recipient Entity
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857151321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $886.00 07/13/2020 Non-covered Recipient Entity
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
AN OPEN-LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF REGN2810 VERSUS THERAPY OF INVESTIGATOR'S CHOICE CHEMOTHERAPY IN RECURRENT OR METASTATIC CERVICAL CARCINOMA No dispute reported 06/30/2026 724470291
Principal investigator 1 GlaxoSmithKline, LLC. $1,925.00 07/02/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB No dispute reported 06/30/2026 734926431
Principal investigator 1 Genentech, Inc. $8,105.00 05/20/2020 Non-covered Recipient Entity
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857151317
Principal investigator 1 GlaxoSmithKline, LLC. $550.00 05/18/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB No dispute reported 06/30/2026 734925527
Principal investigator 1 GlaxoSmithKline, LLC. $7,245.01 05/14/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB No dispute reported 06/30/2026 734923285
Principal investigator 1 Merck Sharp & Dohme Corporation $17.70 05/08/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769479
Principal investigator 1 Merck Sharp & Dohme Corporation $176.16 05/08/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769481
Principal investigator 1 Merck Sharp & Dohme Corporation $188.64 05/08/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769483
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 05/08/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769485
Principal investigator 1 Merck Sharp & Dohme Corporation $30.08 05/08/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740769487
Principal investigator 1 Merck Sharp & Dohme Corporation $13.44 05/08/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740770143
Principal investigator 1 GlaxoSmithKline, LLC. $550.00 05/04/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB No dispute reported 06/30/2026 734927771
Principal investigator 1 Genentech, Inc. $1,500.00 04/06/2020 Non-covered Recipient Entity
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857151311
Principal investigator 1 GlaxoSmithKline, LLC. $895.00 03/05/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB No dispute reported 06/30/2026 734926391
Principal investigator 1 Merck Sharp & Dohme Corporation $23.55 02/10/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740770091
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 02/10/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740770093
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 02/10/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740770095
Principal investigator 1 Merck Sharp & Dohme Corporation $5.76 02/10/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740770133
Principal investigator 1 Merck Sharp & Dohme Corporation $66.06 02/10/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740770135
Principal investigator 1 Merck Sharp & Dohme Corporation $14.10 02/10/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740770137
Principal investigator 1 Merck Sharp & Dohme Corporation $70.74 02/10/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740770139
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 02/10/2020 Non-covered Recipient Entity
NORTHWELL HEALTH MONTER CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 740770141
Principal investigator 1 AstraZeneca Pharmaceuticals LP $89,078.96 02/06/2020 Non-covered Recipient Entity
Biomedical Research Alliance Of New York
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA) No dispute reported 06/30/2026 736737727
Principal investigator 1 GlaxoSmithKline, LLC. $1,020.00 01/16/2020 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB No dispute reported 06/30/2026 734923287